Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival

Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy.

(2017) S. Heon et al.   JOURNAL OF CLINICAL ONCOLOGY

The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis.

(2017) Z. Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases

(2013) A. Ali et al.   Current Oncology

Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

(2013) James W. Welsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients

(2013) Shih-Hsin Hsiao et al.   LUNG CANCER

Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer

(2012) G. L. Ceresoli   CURRENT CANCER DRUG TARGETS

Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: Distinguishing influence of exon 19 deletion on radiographic features

(2012) Akimasa Sekine et al.   LUNG CANCER

EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

(2012) Hsin-Lun Lee et al.   Radiation Oncology

Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation

(2011) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

(2010) S. Heon et al.   CLINICAL CANCER RESEARCH

Phase I Study of Concurrent Whole Brain Radiotherapy and Erlotinib for Multiple Brain Metastases From Non–Small-Cell Lung Cancer

(2009) Joline S.W. Lind et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity

(2008) T. Tanaka et al.   CLINICAL CANCER RESEARCH

Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population

(2008) Shenglin Ma et al.   LUNG CANCER